Lithuania’s Biomatter raises $18M for AI enzyme design
The Next Web
Lithuanian startup Biomatter raised $18M in a Series A round led by Astanor to expand its AI-driven enzyme design platform. The company designs custom enzymes for industrial use, serving clients like AstraZeneca and Thermo Fisher Scientific. Biomatter plans to open a new facility in Vilnius by 2027 and expand its US presence.